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Pancreatic cancer remains a challenge both diagnostically and therapeutically. The typical sites of metastases in pancreatic cancer
include the liver and peritoneum. Other less common sites are the lung, brain, kidney, and bone. Skeletal metastases are less
prevalent in occurrence but contribute to signiﬁcant morbidity associated with pancreatic cancer. The prevalence of osseous
metastases remains unknown but has been estimated to be between 5% and 20%. The most common osseous lesions are osteolytic
in nature, but the osteoblastic ones are extremely rare. Here, we report an interesting case of pancreatic adenocarcinoma with
exclusive bone metastases and discuss brieﬂy the possible pathogenesis.
1.Introduction
The typical sites of metastases in pancreatic cancer include
the liver and peritoneum. Other less common sites are the
lung, brain, kidney, and bone [1, 2]. Skeletal metastases are
less prevalent in occurrence but contribute to signiﬁcant
morbidity associated with pancreatic cancer. The prevalence
of osseous metastases remains unknown but has been
estimatedtobebetween5%and20%[2].Themostcommon
osseous lesions are osteolytic in nature, but the osteoblastic
ones are extremely rare [3–6]. Here, we report an interesting
case of pancreatic adenocarcinoma with exclusive bone
metastases.
Our patient is a 46-year-old African American woman
who wasinitially diagnosed with pancreatic adenocarcinoma
in spring of 2007. A CT scan of chest/abdomen/pelvis
revealed no evidence of metastatic disease, including bones
(Figure 1). She underwent a distal pancreatectomy and
splenectomy. The pathology showed pancreatic ductal
adenocarcinoma and evidence of lymphovascular invasion
with 3 of 18 lymph nodes involved. Her CA19-9 was within
normal limits (<37U/L), and CEA was slightly elevated
at 5.6U/L. Thus, the patient was staged as IIB. She was
subsequently treated with six cycles of gemcitabine (Gemzar;
Eli Lilly). Patient was in clinical remission until July of 2009
when she developed right clavicle pain. A repeat CT scan
showed increased sclerosis of the medial right clavicular
head (Figure 2) with a moth-eaten appearance of the cortex
and medullary space. The diﬀerential diagnosis included
metastasis or chronic osteomyelitis. This was followed by a
PET scan that showed increased tracer uptake in the medial
right clavicle, consistent with either metastatic disease
or osteomyelitis (Figure 3). A ﬁne needle biopsy of the
right clavicle was performed which conﬁrmed metastatic
pancreatic cancer (Figure 4). Upon further investigation,
patient did notice pain in the area of the bone disease on the2 Case Reports in Medicine
Cm
IM: 55 SE: 2
P a g e :5 5o f1 1 4
Figure 1: 46-year-old woman with pancreatic cancer and prior
distal pancreatectomy. CT scan with contrast through the pancreas.
There is calciﬁcation at the cut surface of the pancreas (white
arrow). No residual tumor is seen at this site. Cholecystectomy clips
are present in the gall bladder fossa (black arrow).
right neck area. The patient was started on Zoledronic Acid
(Zometa)and referred to aradiation oncologist. She received
a palliative course of radiation therapy to the aﬀected clavicle
for 2 weeks. As she was near completing her course of
radiation therapy to the clavicle, she complained of new left
hip pain. An MR imaging revealed radiographic evidence of
focal disease in the left ischium, acetabulum, and femur. She
was given an additional dose of ten fractions of radiation
therapy to the hip area. Restaging CT showed interval
progression of metastatic bony disease manifested by a new
lesion in the left sacrum. Patient was started on modiﬁed
FOLFOX6 consisting of 2 weekly cycles of oxaliplatin
85mgm2 i.v. over 2h, together with leucovorin 400mgm2
over 2h, 5-ﬂuorouracil (5-FU) 400mgm2,a n db o l u s ,
followed by a 46-h infusion of 5-FU at 2.4gm2.A f t e ra1 2 -
week therapy with FOFOX regimen, the patient had a repeat
whole body bone scan which showed multiple new foci of
increased uptake as follows: at the base of the skull involving
the cervical spine, L2 and L3 vertebrae, approximate left 5th
and 8th ribs/costovertebral regions of the thoracic spine,
humeri (R >L ), proximal right radius/ulna, upper sacrum,
multiple areas in the left bony pelvis, femora bilaterally,
and left knee; previously noted increased uptake along
the right clavicle appeared more intense compared to the
baseline study. The relentless progression of the disease was
also reﬂected by a signiﬁcant increase in Carcinoembryonic
Antigen(CEA)risingfrom136ng/ml(10/2009)to172ng/ml
(12/2009) (normal range <3ng/ml); CA19.9 remained
<0.8U/ml. Interestingly, there had been no evidence of
soft tissue disease either by the CT (chest/abdomen/pelvis)
or brain MRI. The FOLFOX therapy was discontinued;
her CEA continued to rise reaching 338ng/ml in 02/2010.
Currently, the patient is on best supportive care.
Most patients who develop osseous metastasis have
already concomitant visceral metastases. Our patient devel-
oped metastatic osteoblastic lesion of the clavicle following
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Figure 2: CT scan with contrast through the clavicle. There is
increased sclerosis of the medial right clavicular head (white arrow)
with a moth-eaten appearance of the cortex and medullary space.
The diﬀerential diagnosis is metastasis or chronic osteomyelitis.
Biopsy subsequently showed metastatic pancreatic cancer.
Figure 3: Frontal projection from a bone scan shows increased
tracer uptake in the medial right clavicle, consistent with either
metastatic disease or osteomyelitis. Biopsy conﬁrmed metastatic
pancreatic cancer.
Whipple procedure, and the diagnosis was conﬁrmed by
biopsy of the bone. The uniqueness of this case lies in the
osteoblastic nature and in the absence of visceral metastasis.
Inaretrospective chartreview,patients withbone metastases
uniformly exhibited at least one or more site of disease
with the most common one being the liver followed by the
peritoneum and lungs [1, 6, 7]. One case has reported lesion
in L3 vertebra [2], but we believe that our patient is the
ﬁrst report of pancreatic cancer conﬁned to a distant bone
metastasis (clavicle) as the only site without overt visceral
metastases.Case Reports in Medicine 3
Figure 4: Histological ﬁndings of the clavicle biopsy showing
metastases pancreatic cancer.
Bone involvement in patients with pancreatic cancer may
result from direct posterior extension of the primary tumor
with destruction of the bodies of one or more upper lumbar
vertebrae in the former case [2, 8] while haematogenous
spread may be responsible for our report [3]. Review of
literature also suggests various cytokines such as interleukin-
6[ 9], vascular endothelial growth factor (VEGF), and
parathyroid hormone-related protein (PTHrP) which exert
ap r o m o t i v ee ﬀect on bone resorption and may play a
pivotal role in the development of intraosseous progression
of pancreatic adenocarcinoma [10]. Both osteolytic and
osteoblastic lesions have been described, suggesting multiple
mediators of bone metastases. Transforming growth factor
beta (TGF-b), IL-11, and matrix metalloproteinases have
been shown to stimulate osteoblastic activity in other
tumor types [10]. Additional factors such as ethnic, genetic,
and biologic variables that determine the “homing” and
proliferation of tumor cells remain to be elucidated.
Pancreatic and gastric malignancies demonstrate CEA
level elevations in just over 50% of cases [11]. In a study
conducted by Kokhanenko et al. [12], CA19-9 and CEA
were studied in 685 examinations for PC, 68 chronic pseu-
dotumorous pancreatitis and 24 intestinal cancer at other
sites since 1995. Tumor resection for PC was carried out in
31, conservative treatment in 67, chemotherapy in 56, and
radiotherapyin29cases.InCA19-9examinations,diagnostic
sensitivity was 90.2 speciﬁcity was 72.1 eﬀectiveness was
85.3% while in CEA determinations, 82.5, 30.9, and 68.5%,
respectively. CA19-9 and CEA levels proved to be prognostic
factors of survival. An inverse correlation was observed
between median survival and tumor marker concentrations:
higher basal (preoperative) level of marker in blood was
matchedbylowermediansurvival.Asimilarrelationshipwas
identiﬁed for CEA: 5–10—14.2 months, 10.1–20ng/ml—
8.0 months, 20.1–30ng/ml—3.9 months, and more than
30ng/ml—4.8 months. In our practice, we measure both
markers at baseline and follow the one which was found
elevated at the time of initial assessment.
In conclusion, this case emphasizes individual variability
in the incidence of bone metastases secondary to adenocar-
cinoma of the exocrine pancreas in order to help clinicians
recognize and treat bone metastases early to improve quality
of life and reduce morbidity associated with the progression
of the disease.
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